These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29078022)

  • 1. Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis.
    Mistro S; Gomes B; Rosa L; Miranda L; Camargo M; Badaró R
    Trop Med Int Health; 2017 Dec; 22(12):1569-1578. PubMed ID: 29078022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study.
    Santos CR; Tuon FF; Cieslinski J; de Souza RM; Imamura R; Amato VS
    PLoS One; 2019; 14(6):e0218786. PubMed ID: 31242231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.
    Solomon M; Pavlotzky F; Barzilai A; Schwartz E
    J Am Acad Dermatol; 2013 Feb; 68(2):284-9. PubMed ID: 22858005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.
    Basile G; Cristofaro G; Locatello LG; Vellere I; Piccica M; Bresci S; Maggiore G; Gallo O; Novelli A; Di Muccio T; Gramiccia M; Gradoni L; Gaiera G; Bartoloni A; Zammarchi L
    Int J Infect Dis; 2020 Aug; 97():204-207. PubMed ID: 32505874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
    Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
    de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
    Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.
    Kosaka A; Sakamoto N; Hikone M; Imai K; Ota M; Washino T; Maeda T; Iwabuchi S
    Intern Med; 2020; 59(9):1227-1230. PubMed ID: 32378656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
    Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
    Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.
    Cunha MA; Leão AC; de Cassia Soler R; Lindoso JA
    Am J Trop Med Hyg; 2015 Dec; 93(6):1214-8. PubMed ID: 26483120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraspecies differences in natural susceptibility to amphotericine B of clinical isolates of Leishmania subgenus Viannia.
    Franco-Muñoz C; Manjarrés-Estremor M; Ovalle-Bracho C
    PLoS One; 2018; 13(4):e0196247. PubMed ID: 29698432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
    Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
    Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
    Assis TSM; Rabello A; Cota G; Werneck GL; Azeredo-da-Silva ALF
    Rev Soc Bras Med Trop; 2019 Apr; 52():e20180272. PubMed ID: 30994802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
    Rocio C; Amato VS; Camargo RA; Tuon FF; Nicodemo AC
    Trans R Soc Trop Med Hyg; 2014 Mar; 108(3):176-8. PubMed ID: 24535153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B.
    Machado PR; Rosa ME; Guimarães LH; Prates FV; Queiroz A; Schriefer A; Carvalho EM
    Clin Infect Dis; 2015 Sep; 61(6):945-9. PubMed ID: 26048961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
    Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
    Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.
    Solomon M; Pavlotsky F; Leshem E; Ephros M; Trau H; Schwartz E
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):973-7. PubMed ID: 21129042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical mucocutaneous involvement with Leishmania donovani.
    Pulimood SA; Rupali P; Ajjampur SS; Thomas M; Mehrotra S; Sundar S
    Natl Med J India; 2012; 25(3):148-50. PubMed ID: 22963292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.